Motavizumab for Prophylaxis of Respiratory Syncytial Virus in High-Risk Children: A Noninferiority Trial

Palivizumab reduces respiratory syncytial virus (RSV) hospitalization in children at high risk by approximately 50% compared with placebo. We compared the efficacy and safety of motavizumab, an investigational monoclonal antibody with enhanced anti-RSV activity in preclinical studies, with palivizum...

Full description

Bibliographic Details

Published in:	Pediatrics (Evanston) 2010-01, Vol.125 (1), p.e35-e51
Main Authors:	Carbonell-Estrany, Xavier, Simoes, Eric A.F, Dagan, Ron, Hall, Caroline B, Harris, Brian, Hultquist, Micki, Connor, Edward M, Losonsky, Genevieve A, Motavizumab Study Group
Format:	Article
Language:	eng
Subjects:	Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Antiviral Agents - therapeutic use Child, Preschool Children & youth Confidence Intervals Disease prevention Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Female Follow-Up Studies Hospitalization - statistics & numerical data Humans Infant Infant, Newborn Infant, Premature Kaplan-Meier Estimate Male Medical research Palivizumab Pediatrics Primary Prevention - methods Probability Respiratory Syncytial Virus Infections - drug therapy Respiratory Syncytial Virus Infections - mortality Respiratory Syncytial Virus Infections - prevention & control Respiratory system Risk Assessment Survival Rate Treatment Outcome Viruses
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!